Live Marvell Technology Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow RHYTHM PHARMACEUTICALS, INC.

Get SEC filing alerts via email and in your feed for RHYTHM PHARMACEUTICALS, INC.

RYTM

RHYTHM PHARMACEUTICALS, INC.

About RHYTHM PHARMACEUTICALS, INC.

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing precision medicines targeting the MC4R pathway to treat rare genetic and acquired obesity disorders characterized by hyperphagia and severe obesity. Its lead product, IMCIVREE (setmelanotide), is approved for certain syndromic and monogenic obesity conditions. The company advances clinical programs for hypothalamic obesity and other rare diseases, leveraging genetic insights to expand treatment options for underserved patient populations.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from RHYTHM PHARMACEUTICALS, INC.

1
1
RHYTHM PHARMACEUTICALS, INC. Rhythm Pharmaceuticals Reports 84% Revenue Growth to $60.1 Million in Q1 2026

Via official filing (AI summary) | about 1 month ago | 0 comments

2
1
RHYTHM PHARMACEUTICALS, INC. Rhythm Pharmaceuticals Reports 46% Revenue Growth and Business Update for Fiscal Year 2025

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
RHYTHM PHARMACEUTICALS, INC. Rhythm Pharmaceuticals Reports 54% Revenue Growth in Q3 2025, Faces Increased Losses

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
RHYTHM PHARMACEUTICALS, INC. Rhythm Pharmaceuticals Reports 67% Revenue Growth to $48.5 Million, Net Loss of $46.6 Million for Q2 2025

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
RHYTHM PHARMACEUTICALS, INC. Rhythm Pharmaceuticals Reports 45% Revenue Growth to $37.7 Million in Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
RHYTHM PHARMACEUTICALS, INC. Rhythm Pharmaceuticals Reports 48% Increase in Product Revenue, Net Loss Widens in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments